Sanofi’s Lantus Insulin Patent Infringement Claims Against Mylan Reportedly Rejected R & D Magazine
The U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan N.V. in its inter partes review (IPR) proceedings, finding claims of Sanofi’s …